Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials

Main Article Content

Richard Langley
Dalhousie University

Diamant Thaci
University of Lübeck, Lübeck, Germany

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Tsen-Fang Tsai
National Taiwan University Hospital

Megan Miller
Janssen Research and Development

Jenny Yu
Janssen Research and Development

Yaung-Kaung Shen
Janssen Research and Development

Yin You
Janssen Research and Development

Ya-Wen Yang
Janssen Pharma

Kim Papp
Probity Medical Research, Waterloo, ON, Canada

Luis Puig
Autonomous University of Barcelona

Peter Foley
The University of Melbourne

Keywords

psoriasis

Abstract

N/A

References

1. Armstrong AW et al. Am J Clin Dermatol. 2016;17:329-36;

2. Shalom G et al. J Dermatolog Treat.
2019;30:534-9;

3. Kalb RE et al. JAMA Dermatol. 2015;151:961-9;

4. Blauvelt A et al. J Am Acad
Dermatol. 2017;76:405-17; 5. Reich K et al. J Am Acad Dermatol. 2017;76:418-31.

Article Sidebar

Poster PDF
Published
Mar 4, 2022
DOI https://doi.org/10.25251/skin.6.supp.1

Article Details

How to Cite
Langley, R., Thaci, D., Blauvelt, A. ., Tsai, T.-F., Miller, M. ., Yu, J., Shen, Y.-K. ., You, Y., Yang, Y.-W., Papp, K. ., Puig, L., & Foley, P. (2022). Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, 6(2), s1. https://doi.org/10.25251/skin.6.supp.1
Issue
Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Section
Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>